Fulzerasib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Innovent Biologics Co., Ltd.
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- Treatment of adults with advanced NSCLC harboring a KRAS G12C mutation who have received at least one systemic therapy. This indication received conditional approval based on a single-arm clinical trial. Full approval depends on confirmation of clinical benefit in a confirmatory trial.
- Indication source and scope
- The revision date could not be confirmed from the original file.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Limited to adults with advanced KRAS G12C-mutated NSCLC who have received at least one systemic therapy.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/upload/resources/file/2025/03/18/170990.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://img.innoventbio.com/fzlsp.pdf
Open the interactive record, public price references and discussions